Imfinzi recommended for approval in the EU by CHMP for less- frequent, fixed-dose use in unresectable non-small cell lung cancer
Option would extend dosing from two to four weeks, reducing medical visits and improving patient convenienceAstraZeneca's Imfinzi (durvalumab) has been recommended for marketing authorisation in the European Union (EU) for an additional dosing option, 1,500mg fixed dose every four weeks, in the approved indication of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on at least 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy (CRT). This new dosing option is consistent with the